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Abstract 
The direct negative impact of the transcriptional activity of one component on the second one in cis is referred to 
as transcriptional interference (TI). U6 is a type III RNA polymerase III promoter commonly used for driving 
small hairpin RNA (shRNA) expression in vector-based RNAi. In the design and construction of viral vectors, 
multiple transcription units may be arranged in close proximity in a space-limited vector. Determining if U6 pro-
moter activity can be affected by TI is critical for the expression of target shRNA in gene therapy or 
loss-of-function studies. In this research, we designed and implemented a modified retroviral system where 
shRNA and exogenous gene expressions were driven by two independent transcriptional units. We arranged U6 
promoter driving shRNA expression and UbiC promoter in two promoter arrangements. In primary macrophages, 
we found U6 promoter activity was inhibited by UbiC promoter when in the divergent arrangement but not in 
tandem. In contrast, PKG promoter had no such negative impact. Instead of enhancing U6 promoter activity, 
CMV enhancer had significant negative impact on U6 promoter activity in the presence of UbiC promoter. Our 
results indicate that U6 promoter activity can be affected by TI in a proximal promoter-specific and arrange-
ment-dependent manner. 




RNA interference (RNAi) is an evolutionarily con-
served, sequence-specific gene silencing mechanism 
triggered by two types of RNA in animals: small in-
terfering RNA (siRNA) and microRNA (miRNA). 
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siRNAs are usually generated from precursors in-
cluding transpons, viruses, endogenously expressed 
long double-stranded RNA (dsRNA), or experimen-
tally introduced synthetic dsRNA (1-3), while 
miRNAs are processed products from transcripts of 
endogenous non-coding genes that form small stem 
loops (4-9). RNAi technology provides not only a 
powerful tool for loss-of-function genetic research in 
a variety of systems, but also potentially for in vivo 
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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gene therapy by depleting disease-related transcripts 
while rescuing with the wild-type counterpart. The 
development of vectors encoding small hairpin RNA 
(shRNA) allows for the depletion of disease-related 
transcripts, and has provided potential tools for gene 
therapy (10-14). For these purposes, targeting the 
transcripts with potent and persistent vector-based 
RNAi is the key to the outcome of the treatment. 
So far, several strategies have been tested to en-
hance the efficacy of vector-based RNAi. These in-
clude the design of more efficient RNAi target se-
quence based on different siRNA selection criteria 
(15), the promoter choice of type III RNA polymerase 
III (U6, H1) (16), polymerase II (17-19), shRNA stem 
length (20), loop structure (21), mimicking 
miRNA-based shRNA (22), and addition of U6 leader 
sequence (12). Among these strategies, increasing the 
shRNA expression in the cells is one of the most im-
portant ways to effectively deplete the target tran-
scripts. Recently, U6 promoter has been proved to be 
stronger than H1 promoter in vitro and in vivo (16). 
Enhancing U6 or H1 promoter activity using CMV 
enhancer to increase the shRNA expression in the 
target cells leads to strengthened gene silencing ef-
fects (23, 24). Thus, developing strategies to enhance 
or maintain shRNA potency and dose loading in cells 
is one of the concerns for the design of vector-based 
RNAi. 
The proximal arrangement of two independent 
transcriptional units may affect each other’s activity 
by promoter cross-talk (25). Direct negative impact of 
one transcriptional activity on another in cis is re-
ferred to as transcriptional interference (TI). TI is 
usually asymmetric and results from the existence of 
two promoters, the stronger promoter reduces the ex-
pression of the weaker one. Different promoter ar-
rangements can lead to TI (26). In a viral vector sys-
tem where space is often limited, it is common to 
have multiple transgenes in close proximity to drive 
the expression of a therapeutic transcript or fluores-
cent marker for research purposes (27), thus main-
taining intact U6 promoter activity is critical for suc-
cessful gene silencing. In this research, we study the 
U6 promoter activity regulation by TI within the viral 
vector. We found that U6 promoter activity is inhib-
ited if the shRNA expression cassette is in a divergent 
arrangement with respect to the UbiC promoter, but 
not in the tandem, while PKG promoter has no in-
hibitory effect. The CMV enhancer adjacent to U6 
promoter has significant negative effect on U6 pro-
moter activity in the presence of UbiC promoter. Our 
results suggest that U6 promoter activity can be af-
fected by TI, and this effect is specific to both the 
proximal promoter as well as its arrangement. 
Results 
A modified retroviral system capable of gene 
knockdown and expression  
Mouse primary macrophages are hard to be trans-
fected or nucleofected. However, they can be infected 
with retroviruses. We compared several commercial-
ized retroviral vectors and found that pSuper-
Retro-puro from Oligoengine worked best for virus 
production. It has at least two confirmed features, one 
is the shRNA expression driven by H1 promoter, the 
other is the expression of puromycin drug resistance 
marker driven by PKG promoter. However, H1 pro-
moter may not function with the same strength as a 
U6 promoter for shRNA expression (16), and this 
vector lacks the cloning sites for exogenous gene ex-
pression. We therefore modified this vector into a new 
retroviral vector, capable of gene knockdown and ex-
pression while reserving the puromycin resistance 
expression function. As illustrated in Figure 1A, we 
removed the H1 promoter in pSuperRetro-puro and 
reserved the multiple cloning sites (MCS1) for clon-
ing of U6 promoter driving shRNA expression. Hu-
man UbiC promoter has been shown to be constitu-
tively active in a variety of cells and tissues (27), and 
was selected to drive the expression of an exogenous 
gene and puromycin resistance gene separated by 
SV40 promoter. MCS2 between UbiC and SV40 al-
lows the cloning of exogenous gene. We derived vec-
tors with C-terminal Flag-His6 (FH) to allow for im-
munoblot or immunoprecipitation of the expressed 
protein, and named this new vector as pFRRu. The 
other vector pFRRg has the same design strategy, but 
UbiC promoter was replaced with PKG promoter 
(Figure 1B). With these new retroviral vectors we 
have transduced a variety of mouse cell types (e.g., 
epithelial cells, keratinocytes, fibroblasts, and hema-
topoietic cells) as well as primary cells [e.g., mouse 
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Figure 1  A modified retroviral system with gene knockdown and exogenous gene expression functions. A. Map of the modified 
retroviral vector with UbiC promoter. pFRRu was generated as described in Materials and Methods. There are two multiple cloning 
sites: 5′-end of UbiC has the multiple cloning sites for shRNA expression cassette (MCS1), and 3'-end of UbiC has the multiple 
cloning sites for exogenous gene expression (MCS2) containing an in-frame Flag-His6 (FH) tag. Puromycin (puro) resistance ex-
pression was reserved with SV40 promoter. B. The modified retroviral vector with PKG promoter. UbiC promoter as described above 
was replaced with PKG promoter. 
 
embryonic fibroblasts and bone marrow-derived 
macrophages (BMDMs)]. The efficiency of transduc-
tion varies with cell type and the virus titer applied. 
However, following puromycin selection, all the resid-
ual cells were virally transduced. In this study, the viral 
titer we applied led to 30%-60% transduction effi-
ciency for macrophages, avoiding multiple entries of 
viral transcripts into one cell. 
Inhibition of U6 promoter activity by diver-
gent promoter arrangement of U6 and UbiC 
Usually three promoter arrangements may lead to TI, 
namely convergent promoters, tandem promoters and 
overlapping (divergent) promoters (26). Since con-
vergent promoter arrangement for U6 and other pro-
moters is rare in viral vectors, we focused on tandem 
and divergent promoter arrangements to explore 
which arrangements led to significant impairment to 
U6 promoter activity. We constructed U6 promoter 
driving mCIN85 shRNA expression cassette and in-
serted this expression cassette in MCS1 of pFRRu in 
different orientations. One was divergent promoter 
arrangement in which U6 and UbiC were in opposite 
direction (pU6sh-pUbiC divergent), and the other was 
tandem in the same direction as UbiC (pU6sh-pUbiC- 
tandem). We also generated a luciferase shRNA ex-
pression vector as a non-specific shRNA control and a 
pFRRrfp-U6-mCIN85 shRNA as a control to mini-
mize promoter interaction by replacing UbiC pro-
moter with a non-promoter DNA fragment (Figure 
2A). These vectors were introduced into Plat E cells 
to produce viruses. BMDMs were transduced with 
respective virues and subsequently selected with 
puromycin to remove the non-transduced cells. After 
four days of selection the remaining cells were lysed 
for protein extraction. Western blots were carried out 
using rabbit anti-CIN85 antibody (Figure 2B). Rela-
tive U6 promoter activity was determined using en-
dogenous mCIN85 protein level normalized against 
the α-tubulin level as the loading control. As shown in 
Figure 2C, the arrangement of U6 promoter relative 
to UbiC promoter in the vector had a significant im-
pact on U6 promoter activity. Tandem arrangement 
maintained much higher U6 promoter activity than 
divergent arrangement. This suggested that U6 pro-
moter activity can be regulated by TI in a promoter 
arrangement-dependent manner. 
CMV enhancer negatively impacts U6 pro-
moter activity in the presence of UbiC pro-
moter 
Previous studies have shown that the CMV enhancer 
has a positive effect on U6 promoter activity (23). 
However, the effect of the CMV enhancer on U6 
promoter activity in the presence of TI is unknown. 
To answer this question, we placed a CMV enhancer 
between U6 and UbiC promoters in both promoter 
arrangements by fusing the enhancer to the upstream 
of UbiC or U6 promoter (Figure 3A). We then tested 
the U6 promoter activity. To our surprise, instead of 
enhancing U6 promoter activity, CMV enhancer in all 
four configurations significantly strengthened the 
UbiC inhibitory effect on U6 promoter activity in both 
promoter arrangements (Figure 3B and C). However, 
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Figure 2  Divergent promoter arrangement of U6 and UbiC inhibits U6 promoter activity. A. Diagram of U6 and UbiC promoter 
arrangements. mCIN85 shRNA expression cassette was constructed as described in Materials and Methods, and was inserted into 
pFRRu to form divergent and tandem promoter arrangements. Minimal interfered U6 promoter activity control was set by replacing 
the UbiC promoter with a non-promoter cDNA fragment of RFP. B. Residual endogenous mCIN85 protein level to reflect U6 pro-
moter activity. Mouse BMDMs were transduced with retroviruses produced with different vectors as indicated. Four days after viral 
transduction and drug selection, residual cells were collected and lysed. Western blots were performed using purified rabbit 
anti-CIN85 as primary antibody. C. Normalized mCIN85 knocking down efficiency reflecting relative U6 promoter activity. Sample 
sequences are as indicted in Panel B. Values are statistics from three independent experiments. 
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Figure 3  Negative impact of UbiC on U6 promoter activity enhanced in the presence of CMV enhancer. Legends in Figure 2 was 
followed except that CMV enhancer was placed between U6 and UbiC promoter or fused to the upstream of U6 as plotted. A. Dia-
gram of U6 promoter, CMV enhancer, and UbiC promoter arrangements. CMV enhancer was fused to the upstream of either U6 
promoter or UbiC promoter forming divergent or tandem arrangements as indicated. B. Western blot of mCIN85 to reflect the resid-
ual mCIN85 left in the cells. Samples were generated using different virus transduction as indicated. C. Relative U6 promoter activ-
ity after normalization against α-tubulin. Values are statistics from three independent experiments. 
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the level of inhibition varied with the promoter ar-
rangements. Fusing the CMV enhancer upstream of U6 
and keeping tandem arrangement of the promoters gave 
relatively less inhibition, while the divergent configura-
tion gave the highest inhibition. This result indicates 
that the CMV enhancer can boost TI and significantly 
inhibit U6 promoter activity in the presence of UbiC 
promoter in either promoter arrangements. 
Regulation of U6 promoter activity by TI is 
promoter-specific 
TI is often originated from asymmetric strength of 
two closely arranged promoters, the stronger promoter 
reduces the activity of the weaker one (26). UbiC 
promoter is ubiquitously active in a variety of cells 
and is a relatively strong promoter (27). We next 
asked whether U6 promoter activity can be main-
tained if we replace the UbiC promoter with a weaker 
PKG promoter to balance the previously asymmetric 
strength. We constructed similar viral vectors in both 
U6 promoter arrangements with PKG promoter as 
shown in Figure 4A and tested U6 promoter activity 
in transduced BMDMs. As expected, no significant 
inhibition of U6 promoter activity was observed in 
either arrangement (Figure 4B and C). This result 
suggests that regulation of U6 promoter activity by TI 
is promoter-specific. Balancing the strength of the two 
adjacent promoters is the key. PKG, a weaker promoter, 
has minimum TI effect on U6 promoter activity. 
 
Figure 4  U6 promoter activity response to TI is promoter-specific. Legends in Figure 2 were followed except that UbiC promoter 
was replaced with PKG promoter. A. Diagram of U6 and PKG promoter arrangements. B. Residual endogenous mCIN85 protein 
level to reflect U6 promoter activity. C. Relative U6 promoter activity after normalization against α-tubulin. Values are statistics from 
three independent experiments. 
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Discussion 
In this research, we have designed and implemented a 
retroviral system where shRNA and exogenous gene 
expressions are allowed by two independent tran-
scriptional units. Our results indicate that U6 pro-
moter activity is inhibited when in the divergent ar-
rangement with respect to UbiC promoter, but in tan-
dem arrangement the activity remains unchanged. 
However, PKG promoter has no such impact. Instead 
of enhancing the U6 promoter activity, CMV enhan-
cer has significant negative impact on U6 promoter 
activity by potentiating TI in the presence of UbiC 
promoter in both tandem and divergent promoter ar-
rangements. We demonstrate that U6 promoter activ-
ity can be affected by TI in a promoter arrange-
ment-dependent and proximal promoter-specific 
manner. 
Maintaining U6 promoter activity is crucial for ex-
pression of shRNA in the cells and subsequent deple-
tion of target transcripts in vector-based strategy. In 
designing of vectors for gene therapy or 
loss-of-function research, promoters with different 
strengths may be arranged in a space-limited viral 
vector. TI occurs between two promoters of varying 
strength, where the stronger one suppresses the ac-
tivity of the weaker (26, 28). Since U6 promoter may 
not be strong enough to balance the asymmetry of 
promoter strength, therefore, it is suppressed by the 
adjacent stronger promoter. Our results indicate that 
promoter arrangement is the key for maintaining U6 
promoter activity, providing guidelines for    
maintaining U6 promoter activity in designing viral 
vectors. 
Enhancing U6 promoter activity by CMV enhancer 
in target cells has been proved to be an effective way 
to obtain satisfactory gene silencing (23). U6 pro-
moter is constitutively active in a variety of cell types 
and maintains relatively high activity by providing 
approximately 4×105 transcripts per cell (29). How-
ever, under some circumstances, unmodified Pol III 
promoter is not sufficient to provide satisfactory de-
pletion of target transcripts even without reported TI 
(12, 23, 24, 30-32). The addition of a CMV enhancer 
adjacent to U6 promoter or hybrid CMV-H1 pro-
moter has been reported to improve the efficiency of 
RNAi (23, 24) or shRNA delivery in vivo (33). Our 
results indicate that in a relative more complex vec-
tor niche, addition of CMV enhancer adjacent to U6 
promoter may even enhance the asymmetry of the 
two independent transcriptional units and potentiate 
suppression to U6 promoter activity by enhancing TI 
in either divergent or tandem promoter arrangement. 
Materials and Methods 
Cell culture 
Human embryonic kidney 293T cells and retroviral 
packaging cell line Plat E cells (30) were maintained 
in DMEM-10 (DMEM containing 10% FBS, Gluta-
mine and pen/str). Mouse primary BMDMs were 
isolated and cultured using alpha-10 (alpha MEM 
containing 10% FBS, Glutamine and pen/str) and a 
conditional medium containing M-CSF as described 
(31). 
Antibodies 
Mouse monoclonal α-tubulin antibody and rabbit 
anti-CIN85 antibody were purchased from Sigma. 
Construction of multifunctional retroviral  
vectors 
UbiC promoter containing multiple cloning sites was 
amplified by PCR using pFG12 (16) as template. 
SV40-puro fragment was obtained by PCR using 
pMX-puro as template (32). These two fragments 
were spliced together using joint PCR and were 
cloned into BglII/SacII sites in pSuper-Retro-puro 
(Oligoengine), and we named this new vector as 
pFRRu. The other vector pFRRg was obtained by 
replacing UbiC promoter in pFRRu with PCR frag-
ment of PKG promoter. CMV enhancer was obtained 
by PCR using pDsRed2 (Clontech) as template with 
primer pairs: TCTAGAAGATCTCGCGTTACATAA 
CTTACGGTAAATG (forward), AGTCGGATCC  
AAAACAAACTCCCATTGACGTCAATG (reverse). 
BamHI/BglII-cut CMV enhancer fragment was fused 
to UbiC promoter by a subcloning into BglII site of 
pFRRu. Modified regions of these vectors were con-
firmed by sequencing.  
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mCIN85 shRNA expression cassette 
Mouse CIN85 shRNA target sequence was predicted 
with Rational_siRNA_Design Program (33). We se-
lected target sequence in the 3'-UTR of mCIN85 
mRNA: GCTACCATGATTCCAAATAA.  
Mouse CIN85 shRNA expression cassette was 
constructed by joint PCR. Briefly, we obtained the 
hU6 promoter (f1) by PCR using pBS-hU6-1 as tem-
plate (16) with primer pairs p1 and p2, and the shRNA 
fragment (f2) was obtained by PCR using primer pairs 
p3 and p4 (Table 1).  
After electrophoresis, f1 was purified from a 1% 
TAE-agrose gel with gel purification kit (Invitrogen) 
while f2 was purified from a 12% TAE-polyacrylamide 
gel. Joint PCRs were carried out using hU6 forward 
primer p1, shRNA reverse primer p4 and mixed tem-
plate of f1 and f2. The PCR products were purified, 
cut with BglII/XhoI and subcloned into a pFRRu or 
pFRRg vector as depicted in the text. To change the 
orientation of U6-driven shRNA expression cassette 
in the vectors, we re-amplified the above shRNA ex-
pression cassette with PCR primer pairs p5 and p6 
(Table 1). This fragment was cut with SalI/BamHI 
and was cloned into XhoI/BglII-cut pFRRu. All con-
structs containing shRNA expression cassette se-
quence were sequenced using hU6 forward primer p1. 
Retrovirus production and transduction of 
mouse BMDMs 
Protocols described in Ilves et al (31) were followed 
with some modifications. Briefly, a subconfluent cul-
ture of Plat E cells in six-well plate was transfected 
with pFRRu- or pFRRg-derived plasmids. After 24 h, 
cells were washed once with LPS-free alpha-10, and 
fresh alpha-10 was applied in each well for another 24 
h to accumulate viruses. Viruses were collected and 
filtered with 0.45-μm syringe filter and mixed with 
equal volumes of alpha-10, and 10% conditional me-
dium containing M-CSF (equivalent to 10 ng/mL 
M-CSF final) and protamine (10 μg/mL final, pur-
chased from Sigma). The prepared medium was ap-
plied to the BMDMs for overnight infection, and the 
infected BMDMs were further cultured in fresh al-
pha-10 containing 10% M-CSF conditional medium 
and puromycin (3.5 μg/mL final) for four days to re-
move non-transduced cells. This protocol allowed 
about 30%-60% viral transduction efficiency. Resid-
ual cells after drug selection were considered as vi-
ral-transduced. The cells were collected and washed 
with 1×PBS and lysed with cell lysis buffer [20 mM 
Hepes pH 7.6, 300 mM NaCl, 0.5 mM EDTA, 5 mM 
NaF, 1 mM sodium orthovanadate, 5% glycerol, 0.1% 
NP-40, 1 mM DTT, protease inhibitor cocktail 
(Sigma)]. Protein concentration was measured with 
Bio-Rad rapid protein assay kit. For Western blot 
analysis, 20 μg of cell lysate was loaded to each lane.  
Indirect U6 promoter activity assay 
In this research, U6 promoter activity was defined as 
the percentage of endogenous mCIN85 depletion. 
Residual endogenous mCIN85 and α-tubulin protein 
level were determined by Western blot. Bar-charts 
were plotted by measuring the density of mCIN85 
bands in the film by ImageJ while using α-tubulin 
band density as loading control for normalization. 
Table 1  PCR primer pairs used for mouse CIN85 shRNA expression cassette 
Primer Sequence Orientation 
p1 GCACAGATCTATCTAGAACCCCAGTGGAAAGACGCGCAG forward 
p2 GGTGTTTCGTCCTTTCCACAAG reverse 
p3 GTGGAAAGGACGAAACACCGCTACCATGATTCCAAATAATTCAAGAGATTATTTG forward 
p4 TCCAGCTCGAGAAAAAGCTACCATGATTCCAAATAATCTCTTGAATTATTTG reverse 
p5 AGCTGTCGACAGATCTATCTAGAACCCCAGTGGAAAGACGCGCAG forward 
p6 TCCAGGGATCCCTCGAGAAAAAGCTACCATGATTCCAAATAATCTCTTG reverse 
Note: Nucleotides in italics are hairpin sequences while in bold face are target siRNA sequences. 
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